1. Home
  2. KG vs LUNG Comparison

KG vs LUNG Comparison

Compare KG & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KG

Kestrel Group Ltd.

HOLD

Current Price

$5.00

Market Cap

87.3M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.88

Market Cap

97.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KG
LUNG
Founded
N/A
1995
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.3M
97.1M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
KG
LUNG
Price
$5.00
$1.88
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.40
AVG Volume (30 Days)
11.7K
★ 257.3K
Earning Date
11-04-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1819.15
7.64
EPS
N/A
★ N/A
Revenue
$34,049,000.00
★ $90,497,000.00
Revenue This Year
N/A
$0.06
Revenue Next Year
N/A
$8.58
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 785.08
8.01
52 Week Low
$4.31
$1.13
52 Week High
$26.44
$2.89

Technical Indicators

Market Signals
Indicator
KG
LUNG
Relative Strength Index (RSI) 46.63 50.15
Support Level $4.50 $1.70
Resistance Level $5.59 $2.12
Average True Range (ATR) 0.44 0.11
MACD 0.11 0.01
Stochastic Oscillator 63.67 74.42

Price Performance

Historical Comparison
KG
LUNG

About KG Kestrel Group Ltd.

Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: